Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.

Erin G ReidAdrienne SuazoShelly Y LensingDirk P DittmerRichard F AmbinderFrank MaldarelliRobert J GorelickDavid AboulafiaRonald MitsuyasuMark A DicksonWilliam Wachsmannull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Bortezomib is well-tolerated and active in AIDS-Kaposi sarcoma. The 60% PR rate is notable given the dose-finding nature of the study in a r/r population. Changes in KSHV PDCN and HIV VL trended as hypothesized.

Keyphrases

antiretroviral therapy
multiple myeloma
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
newly diagnosed
hiv testing
hepatitis c virus
men who have sex with men
south africa